Table 1.
Study | Age | Study population | Patients | PSA level | Prostate volume | Biopsy methods | |||
---|---|---|---|---|---|---|---|---|---|
TP group | TR group | TP group | TR group | TP group | TR group | ||||
Hara et al., 2008, Japan [21] | 71 | Patients with a PSA level of 4.0 to 20.0 ng/mL from 2003.5 to 2005.10 | 126 | 120 | 8.34 | 8.48 | 33.2 | 36 | Systematic 12-core biopsy |
Takenaka et al., 2008, Japan [22] | 71 in TP group, 72 in TR group | Consecutive patients with an elevated PSA level (> 4 ng/mL) | 100 | 100 | 17.1 | 19.6 | 34.5 | 37.2 | Systematic 12-core biopsy |
Cerruto et al., 2014, Italy [23] | 66.5 in TP group, 67.3 in TR group | Consecutive patients with a PSA > 4 ng/mL | 54 | 54 | 15.95 | 12.36 | 56.29 | 61.49 | Systematic 14-core initial prostatic biopsy |
Guo et al., 2015, China [20] | 67 | Patients between 2012.6 and 2014.8 with a PSA > 4.0 ng/ml | 173 | 166 | 8.81 | 10.48 | 47.2 | 45.9 | Systematic 12-core biopsy |
Abbreviations: TP transperineal, TR transrectal, PSA prostate-specific antigen